ARTICLE | Company News

NicOx autoimmune news

August 9, 2010 7:00 AM UTC

NicOx will close its U.S. headquarters, NicOx Inc., effective Aug. 31 after FDA issued a complete response letter for an NDA for naproxcinod to treat signs and symptoms of osteoarthritis (OA). The closure of the facility, which is responsible for commercial and clinical activities, will result in headcount reductions of 22 (18%) to 102. Naproxcinod is a cyclooxygenase (COX)-inhibiting nitric oxide donator (CINOD) that releases naproxen and nitric oxide. ...